GCG and type 2 diabetes mellitus: Taken together with the known clinical effectiveness of GLP-1 mimetics and DPP-4 inhibitors in Type 2 diabetes, the data suggest that exploring the opportunities to stimulate the entero-endocrine axis in vivo might reveal exciting new therapeutic possibilities.